Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 1, n. 3.1, p. s129, 2017. DOI: 10.25251/skin.1.supp.128. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/76. Acesso em: 3 jul. 2024.